Loss of expression of a new member of the DNAJ protein family confers resistance to chemotherapeutic agents used in the treatment of ovarian cancer.

Shridhar, V

Loss of expression of a new member of the DNAJ protein family confers resistance to chemotherapeutic agents used in the treatment of ovarian cancer. [electronic resource] - Cancer research May 2001 - 4258-65 p. digital

Publication Type: Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.

0008-5472


Amino Acid Sequence
Azacitidine--analogs & derivatives
Base Sequence
Chromosome Mapping
Cisplatin--pharmacology
Cloning, Molecular
DNA, Neoplasm--genetics
Decitabine
Down-Regulation
Drug Resistance, Multiple--genetics
Drug Resistance, Neoplasm
Female
Gene Expression Regulation, Neoplastic
Gene Silencing
HSP40 Heat-Shock Proteins
Heat-Shock Proteins--biosynthesis
Humans
In Situ Hybridization, Fluorescence
Loss of Heterozygosity
Molecular Sequence Data
Ovarian Neoplasms--drug therapy
Oximes
Paclitaxel--pharmacology
Piperazines
Reverse Transcriptase Polymerase Chain Reaction
Sequence Homology, Amino Acid
Topotecan--pharmacology
Transfection
Tumor Cells, Cultured